Allogene Therapeutics (ALLO) Stock Price, News & Analysis

-0.07 (-2.02%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.79 million shs
Average Volume
2.57 million shs
Market Capitalization
$574.91 million
P/E Ratio
Dividend Yield
Price Target

Allogene Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
280.5% Upside
$12.94 Price Target
Short Interest
29.33% of Float Sold Short
Dividend Strength
News Sentiment
1.15mentions of Allogene Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$684 Bought Last Quarter
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.99 out of 5 stars

Medical Sector

526th out of 910 stocks

Biological Products, Except Diagnostic Industry

84th out of 154 stocks

ALLO stock logo

About Allogene Therapeutics Stock (NASDAQ:ALLO)

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

ALLO Stock Price History

ALLO Stock News Headlines

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update
The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
3 Meme Stocks to Sell and Replace With Meme Coins
The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
ALGS Apr 2024 2.500 call
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$3.04 per share


Free Float
Market Cap
$574.91 million

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Arie S. Belldegrun F.A.C.S. (Age 75)
    M.D., Co-Founder & Executive Chairman
    Comp: $714.25k
  • Dr. David D. Chang M.D. (Age 64)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $1.1M
  • Mr. Joshua A. Kazam (Age 47)
    Co-Founder & Director
    Comp: $711k
  • Mr. Timothy L. Moore Ph.D. (Age 63)
    Executive VP & Chief Technical Officer
  • Mr. Earl M. Douglas Esq. (Age 61)
    General Counsel & Compliance Officer
  • Ms. Susan R. Lundeen (Age 58)
    Chief People Officer
  • Ms. Christine Cassiano
    Executive VP, Chief Corporate Affairs & Brand Strategy Officer
  • Dr. Zachary J. Roberts M.D. (Age 46)
    Ph.D., Executive VP of Research & Development and Chief Medical Officer
  • Yinlin Chen
    Senior Vice President of Finance
  • Mr. David M. Tanen J.D. (Age 53)

ALLO Stock Analysis - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 12-month price objectives for Allogene Therapeutics' shares. Their ALLO share price targets range from $7.00 to $28.00. On average, they anticipate the company's stock price to reach $12.94 in the next year. This suggests a possible upside of 280.5% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How have ALLO shares performed in 2024?

Allogene Therapeutics' stock was trading at $3.21 on January 1st, 2024. Since then, ALLO shares have increased by 5.9% and is now trading at $3.40.
View the best growth stocks for 2024 here

Are investors shorting Allogene Therapeutics?

Allogene Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 30,620,000 shares, an increase of 10.3% from the March 15th total of 27,750,000 shares. Based on an average daily volume of 2,610,000 shares, the short-interest ratio is currently 11.7 days. Approximately 29.3% of the company's stock are short sold.
View Allogene Therapeutics' Short Interest

When is Allogene Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ALLO earnings forecast

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.04. The company earned $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. Allogene Therapeutics had a negative trailing twelve-month return on equity of 53.76% and a negative net margin of 202,366.25%.

What ETFs hold Allogene Therapeutics' stock?
What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

Allogene Therapeutics (ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.09%) and Bourgeon Capital Management LLC (0.03%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Eric Thomas Schmidt, Geoffrey M Parker, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri.
View institutional ownership trends

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALLO) was last updated on 4/23/2024 by Staff

From Our Partners